Amyotrophic Lateral Sclerosis Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Amylyx Pharma, Ionis Pharma, Annexon, Inc., UniQure Biopharma, Sangamo Therapeutics

Posted on
by

Amyotrophic Lateral Sclerosis Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Amylyx Pharma, Ionis Pharma, Annexon, Inc., UniQure Biopharma, Sangamo Therapeutics
The Amyotrophic Lateral Sclerosis Market Forecast-2034 report offers an in-depth understanding of the Amyotrophic Lateral Sclerosis, historical and forecasted epidemiology as well as the Amyotrophic Lateral Sclerosis market trends in the 7MM.

DelveInsight’s “Amyotrophic Lateral Sclerosis Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Amyotrophic Lateral Sclerosis, historical and forecasted epidemiology as well as the Amyotrophic Lateral Sclerosis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

The latest healthcare forecast report provides an in-depth analysis of Amyotrophic Lateral Sclerosis, offering comprehensive insights into the Amyotrophic Lateral Sclerosis revenue trends, prevalence, and treatment landscape. The report delves into key Amyotrophic Lateral Sclerosis statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Amyotrophic Lateral Sclerosis therapies. Additionally, we cover the landscape of Amyotrophic Lateral Sclerosis clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Amyotrophic Lateral Sclerosis treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Amyotrophic Lateral Sclerosis space.

 

To Know in detail about the Amyotrophic Lateral Sclerosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Amyotrophic Lateral Sclerosis Market Forecast

 

Some of the key facts of the Amyotrophic Lateral Sclerosis Market Report: 

  • The Amyotrophic Lateral Sclerosis market size was valued ~USD 1 billion in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)

  • Key Amyotrophic Lateral Sclerosis Companies: AB Sciences, NeuroSense Therapeutics, Prilenia therapeutics, Corcept Therapeutics, AL-S Pharma, Woolsey Pharmaceuticals, Amylyx Pharmaceuticals Inc., Ionis Pharmaceuticals, Annexon, Inc., UniQure Biopharma B.V., Sangamo Therapeutics, PTC Therapeutics, Ferrer Internacional S.A., Cytokinetics, Helixmith Co., Ltd., GlaxoSmithKline, Mallinckrodt, Clene Nanomedicine, Knopp Biosciences, Neuraltus Pharmaceuticals, Inc., PTC Therapeutics, Clene Nanomedicine, and others

  • Key Amyotrophic Lateral Sclerosis Therapies: Masitinib, PrimeC, Pridopidine, Dazucorilant, AP-101, Fasudil (WP-0512), AMX0035, ION363, ANX005, AMT-162, SB-509, PTC857, FAB122, Reldesemtiv, VM202, Ozanezumab, Repository corticotropin injection, CNM-Au8, KNS-760704, NP001, EPI-589, CNMAu8l, and others

  • In February 2024, Biogen Inc. (Nasdaq: BIIB) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion, recommending exceptional marketing authorization for QALSODY® (tofersen) to treat adults with amyotrophic lateral sclerosis (ALS) associated with a mutation in the superoxide dismutase 1 (SOD1) gene. If approved by the European Commission (EC), QALSODY will become the first treatment in the European Union targeting a genetic cause of ALS, also known as motor neuron disease (MND).

  • In February 2024, 4B Technologies has developed FB1006, an AI-discovered and developed drug, from target identification to efficacy assessment, as a potential new treatment for ALS. The company has completed patient enrollment for its investigator-initiated clinical trial (IIT), involving 64 participants. Conducted at the Third Hospital of Peking University, the trial is set to finish double-blind dosing by August 2024 and conclude the one-year clinical observation in February 2025.

  • In 2023, the market size for Amyotrophic Lateral Sclerosis in the US was estimated at approximately USD 920 million, with expectations for growth throughout the forecast period from 2024 to 2034.

  • RADICAVA is expected to be the top performer in the Amyotrophic Lateral Sclerosis market, projected to generate the highest revenue of USD 923 million in the US by 2034.

  • By 2034, among the new therapies, Masitinib combined with riluzole is expected to generate the highest revenue in Japan, reaching USD 37 million.

  • The Amyotrophic Lateral Sclerosis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Amyotrophic Lateral Sclerosis pipeline products will significantly revolutionize the Amyotrophic Lateral Sclerosis market dynamics.

  • In 2023, the number of diagnosed prevalent cases of Amyotrophic Lateral Sclerosis across the seven major markets was approximately 60,600.

  • Amyotrophic Lateral Sclerosis can be categorized based on the types of mutations causing the condition into C9ORF72, SOD1, FUS, various other mutations (such as TARDBP, OPTN, ANG), and cases with non-mutated or unidentified mutations.

  • In 2023, there were approximately 38,200 cases of Amyotrophic Lateral Sclerosis with a spinal site of onset, about 17,800 cases with a bulbar site of onset, and around 4,500 cases with onset in other uncertain regions across the seven major markets.

  • ALS is more prevalent in males compared to females. In the United States, there were 15,400 diagnosed cases of Amyotrophic Lateral Sclerosis in males and 11,200 in females in 2023.

  • In February 2024, Denali Therapeutics was informed by Sanofi that the Phase II HIMALAYA study evaluating SAR443820/DNL788 in participants with ALS did not meet the primary endpoint of change in ALS functional rating scale-revised (ALSFRS-R).

  • In April 2023, the United states Food and Drug Administration (US FDA) approved QALSODY (tofersen) for treating individuals with ALs associated with a mutation in the superoxide dismutase 1 (SOD1) gene (SOD1-ALS).

  • Kadimastem conducted a Phase I/IIa study of AstroRx for the treatment of patients with ALS. Moreover, the results of the clinical trial demonstrated a high safety profile of AstroRx cells. In addition to that, the company is now moving forward with all the activities needed to test multiple injections of AstroRx cells in the next clinical trials.

 

Amyotrophic Lateral Sclerosis Overview

Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord. It leads to the gradual loss of motor neurons, which are responsible for controlling voluntary muscles. As these neurons degenerate, individuals experience muscle weakness, atrophy, and eventually, loss of motor function. Symptoms typically begin with muscle twitches and weakness in one part of the body and progressively spread. ALS often leads to severe disability and, ultimately, respiratory failure. While there is no cure, treatments aim to manage symptoms and improve quality of life.

 

Get a Free sample for the Amyotrophic Lateral Sclerosis Market Forecast, Size & Share Analysis Report: 

https://www.delveinsight.com/report-store/amyotrophic-lateral-sclerosis-als-market

 

Amyotrophic Lateral Sclerosis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Amyotrophic Lateral Sclerosis Epidemiology Segmentation:

The Amyotrophic Lateral Sclerosis market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Prevalence of Amyotrophic Lateral Sclerosis

  • Prevalent Cases of Amyotrophic Lateral Sclerosis by severity

  • Gender-specific Prevalence of Amyotrophic Lateral Sclerosis

  • Diagnosed Cases of Episodic and Chronic Amyotrophic Lateral Sclerosis

 

Download the report to understand which factors are driving Amyotrophic Lateral Sclerosis epidemiology trends @ Amyotrophic Lateral Sclerosis Epidemiology Forecast

 

Amyotrophic Lateral Sclerosis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Amyotrophic Lateral Sclerosis market or expected to get launched during the study period. The analysis covers Amyotrophic Lateral Sclerosis market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Amyotrophic Lateral Sclerosis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Amyotrophic Lateral Sclerosis Therapies and Key Companies

  • Masitinib : AB Sciences

  • PrimeC : NeuroSense Therapeutics

  • Pridopidine : Prilenia therapeutics

  • Dazucorilant: Corcept Therapeutics

  • AP-101: AL-S Pharma

  • Fasudil (WP-0512): Woolsey Pharmaceuticals

  • AMX0035: Amylyx Pharmaceuticals Inc.

  • ION363: Ionis Pharmaceuticals

  • ANX005: Annexon, Inc.

  • AMT-162: UniQure Biopharma B.V.

  • SB-509: Sangamo Therapeutics

  • PTC857: PTC Therapeutics

  • FAB122: Ferrer Internacional S.A.

  • Reldesemtiv: Cytokinetics

  • VM202: Helixmith Co., Ltd.

  • Ozanezumab: GlaxoSmithKline

  • Repository corticotropin injection: Mallinckrodt

  • CNM-Au8: Clene Nanomedicine

  • KNS-760704: Knopp Biosciences

  • NP001: Neuraltus Pharmaceuticals, Inc.

  • EPI-589: PTC Therapeutics

  • CNMAu8: Clene Nanomedicine

 

Discover more about therapies set to grab major Amyotrophic Lateral Sclerosis market share @ Amyotrophic Lateral Sclerosis Treatment Landscape

 

Amyotrophic Lateral Sclerosis Market Strengths

  • Pridopidine is administered in an easy-to-swallow capsule twice daily, offering patient friendly RoA.

  • Most of the 7MM possess their own ALS registries, thereby providing a near precise country-wise number for diagnosed prevalent cases of the disease.

 

Amyotrophic Lateral Sclerosis Market Opportunities

  • As various ALS-causing mutations have been identified, key players have a great opportunity to develop therapies targeting these mutations.

  • There is a need for biomarkers specific drugs that can assist in improvement in the overall health of ALS patients.

 

Scope of the Amyotrophic Lateral Sclerosis Market Report

  • Study Period: 2020–2034

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Amyotrophic Lateral Sclerosis Companies: AB Sciences, NeuroSense Therapeutics, Prilenia therapeutics, Corcept Therapeutics, AL-S Pharma, Woolsey Pharmaceuticals, Amylyx Pharmaceuticals Inc., Ionis Pharmaceuticals, Annexon, Inc., UniQure Biopharma B.V., Sangamo Therapeutics, PTC Therapeutics, Ferrer Internacional S.A., Cytokinetics, Helixmith Co., Ltd., GlaxoSmithKline, Mallinckrodt, Clene Nanomedicine, Knopp Biosciences, Neuraltus Pharmaceuticals, Inc., PTC Therapeutics, Clene Nanomedicine, and others

  • Key Amyotrophic Lateral Sclerosis Therapies: Masitinib, PrimeC, Pridopidine, Dazucorilant, AP-101, Fasudil (WP-0512), AMX0035, ION363, ANX005, AMT-162, SB-509, PTC857, FAB122, Reldesemtiv, VM202, Ozanezumab, Repository corticotropin injection, CNM-Au8, KNS-760704, NP001, EPI-589, CNMAu8, and others

  • Amyotrophic Lateral Sclerosis Therapeutic Assessment: Amyotrophic Lateral Sclerosis current marketed and Amyotrophic Lateral Sclerosis emerging therapies

  • Amyotrophic Lateral Sclerosis Market Dynamics: Amyotrophic Lateral Sclerosis market drivers and Amyotrophic Lateral Sclerosis market barriers 

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Amyotrophic Lateral Sclerosis Unmet Needs, KOL’s views, Analyst’s views, Amyotrophic Lateral Sclerosis Market Access and Reimbursement 

 

To know more about Amyotrophic Lateral Sclerosis companies working in the treatment market, visit @ Amyotrophic Lateral Sclerosis Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Amyotrophic Lateral Sclerosis Market Report Introduction

2. Executive Summary for Amyotrophic Lateral Sclerosis

3. SWOT analysis of Amyotrophic Lateral Sclerosis

4. Amyotrophic Lateral Sclerosis Patient Share (%) Overview at a Glance

5. Amyotrophic Lateral Sclerosis Market Overview at a Glance

6. Amyotrophic Lateral Sclerosis Disease Background and Overview

7. Amyotrophic Lateral Sclerosis Epidemiology and Patient Population

8. Country-Specific Patient Population of Amyotrophic Lateral Sclerosis 

9. Amyotrophic Lateral Sclerosis Current Treatment and Medical Practices

10. Amyotrophic Lateral Sclerosis Unmet Needs

11. Amyotrophic Lateral Sclerosis Emerging Therapies

12. Amyotrophic Lateral Sclerosis Market Outlook

13. Country-Wise Amyotrophic Lateral Sclerosis Market Analysis (2020–2034)

14. Amyotrophic Lateral Sclerosis Market Access and Reimbursement of Therapies

15. Amyotrophic Lateral Sclerosis Market Drivers

16. Amyotrophic Lateral Sclerosis Market Barriers

17.  Amyotrophic Lateral Sclerosis Appendix

18. Amyotrophic Lateral Sclerosis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
City: Las vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services